Vascular mimicry: Concepts and implications for anti-angiogenic therapy

Current Angiogenesis

Volumn 1, Issue 2, 2012, Pages 133-138

  Dunleavey, James M ^a   Dudley, Andrew C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Tumor; Tumor endothelial cells; Tumor microenvironment; Vascular mimicry

Indexed keywords

AG28262; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CD31 ANTIGEN; CD34 ANTIGEN; ENDOSTATIN; EPHRIN RECEPTOR A2; KALININ; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTIGEN EXPRESSION; ASTROCYTOMA; BREAST CANCER; DRUG MECHANISM; ECTODERM; ENDODERM; EWING SARCOMA; GLIOBLASTOMA; HEMANGIOPERICYTOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MESODERM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR; TUMOR CELL; UVEA MELANOMA; VASCULAR MIMICRY;

EID: 84933046458     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201020133     Document Type: Review

References (56)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
2. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011; 10(6): 417-427.
3. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155(3): 739-752.
4. McDonald DM, Munn L, Jain RK. Vasculogenic mimicry: how convincing, how novel, and how significant? Am J Pathol 2000; 156(2): 383-388.
5. Francois J. Malignant Melanomata of the Choroid. Br J Ophthalmol 1963; 47: 736-743.
6. Francois J, Neetens A. Physico-anatomical studies of spontaneous and experimental intraocular newgrowths: vascular supply. Biol Anat 1967; 9: 403-411.
7. Jensen OA. Malignant melanoma of the choroid of a peculiar cavernous type. Clinical manifestation by hemorrhage of the vitreous body. Arch Ophthalmol 1964; 72: 337-340.
8. Jensen OA. The Knapp-Ronne type of malignant melanoma of the choroid. A haemangioma-like melanoma with a typical clinical picture. So-called preretinal malignant choroidal melanoma. Acta Ophthalmol (Copenh) 1976; 54(1): 41-54.
9. Hammersen F, Endrich B, Messmer K. The fine structure of tumor blood vessels. I. Participation of non-endothelial cells in tumor angiogenesis. Int J Microcirc Clin Exp 1985; 4(1): 31-43.
10. Prause JU, Jensen OA. Scanning electron microscopy of frozencracked, dry-cracked and enzyme-digested tissue of human malignant choroidal melanomas. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1980; 212(3-4): 217-225.
11. Chang YS, Di Tomaso E, McDonald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 2000; 97(26): 14608-1413.
12. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468(7325): 829-833.
13. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468(7325): 824-848.
14. Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Nat Acad of Sci 2011; 108(11): 4274-480.
15. Bautch VL. Cancer: Tumour stem cells switch sides. Nature 2010; 468(7325): 770-771.
16. Shirakawa K, Wakasugi H, Heike Y, et al. Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002; 99(6): 821-828.
17. Sood AK, Seftor EA, Fletcher MS, et al. Molecular determinants of ovarian cancer plasticity. Am J Pathol 2001; 158(4): 1279-1288.
18. Sood AK, Fletcher MS, Zahn CM, et al. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 2002; 1(6): 661-664.
19. Sharma N, Seftor REB, Seftor EA, et al. Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: Role in vasculogenic mimicry. Prostate 2002; 50(3): 189-201.
20. van der Schaft DWJ, Hillen F, Pauwels P, et al. Tumor Cell Plasticity in Ewing Sarcoma, an Alternative Circulatory System Stimulated by Hypoxia. Cancer Res 2005; 65(24): 11520-1158.
21. Zhang Z, Han Y, Zhang K, Teng L. Investigation of vasculogenic mimicry in intracranial hemangiopericytoma. Mol Med Report 2011; 4(6): 1295-1298.
22. Liu Z, Li Y, Zhao W, Ma Y, Yang X. Demonstration of vasculogenic mimicry in astrocytomas and effects of Endostar on U251 cells. Pathol Res Pract 2011; 207(10): 645-651.
23. Guzman G, Cotler SJ, Lin AY, Maniotis AJ, Folberg R. A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med 2007; 131(12): 1776-1781.
24. El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 2010; 133(4): 973-982.
25. Passalidou E, Trivella M, Singh N, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002; 86(2): 244-249.
26. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006; 5(2): 228-233.
27. Seftor RE, Seftor EA, Koshikawa N, et al. Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 1(17): 6322-6327.
28. Seftor EA, Meltzer PS, Schatteman GC, et al. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol 2002; 44(1): 17-27.
29. Seftor EA, Meltzer PS, Kirschmann DA, et al. Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis 2002; 19(3): 233-246.
30. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406(6795): 536-540.
31. Hendrix MJ, Seftor EA, Meltzer PS, et al. Expression and functionalsignificance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001; 98(14): 8018-8023.
32. Pisacane AM, Picciotto F, Risio M. CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma. Cell Oncol 2007; 29(1): 59-66.
33. Spannuth WA, Nick AM, Jennings NB, et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer 2009; 124(5): 1045-1053.
34. Topczewska JM, Postovit L, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006; 12(8): 925-932.
35. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49(3): 507-521.
36. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7(10): 803-815.
37. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998; 152(2): 399-411.
38. Ruf W, Seftor EA, Petrovan RJ, et al. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res 2003; 63(17): 5381-5389.
39. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2(4): 266-276.
40. Clarijs R, Otte-Höller I, Ruiter DJ, de Waal RMW. Presence of a Fluid-Conducting Meshwork in Xenografted Cutaneous and Primary Human Uveal Melanoma. Investig Ophthalmol Vis Sci 2002; 43(4): 912-918.
41. Kobayashi H, Shirakawa K, Kawamoto S, et al. Rapid Accumulation and Internalization of Radiolabeled Herceptin in an Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-enhanced Dynamic MRI with the MacromolecularContrast Agent G6-(1B4M-Gd)256. Cancer Res 2002; 62(3): 860-866.
42. Frenkel S, Barzel I, Levy J, et al. Demonstrating circulation in vasculogenic mimicry patterns of uveal melanoma by confocal indocyanine green angiography. Eye (Lond) 2008; 22(7): 948-952.
43. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007; 7(4): 246-255.
44. Kulesa PM, Kasemeier-Kulesa JC, Teddy JM, et al. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci USA 2006; 103(10): 3752-3757.
45. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3(6): 411-421.
46. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 2004; 64(15): 5270-5282.
47. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002; 1(3): 279-288.
48. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol 2007; 20(1): 102-107.
49. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65(10): 4320-4333.
50. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-likecells give rise to tumour endothelium. Nature 2010; 468(7325): 829-833.
51. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975; 141(2): 427-439.
52. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer 2008; 8(8): 579-591.
53. Bergers G, Hanahan D. Modes of resistance to anti-angiogenictherapy. Nat Rev Cancer 2008; 8(8): 592-603.
54. Stone EM. A very effective treatment for neovascular macular degeneration. N Engl J Med 2006; 355(14): 1493-1495.
55. van der Schaft DWJ, Seftor REB, Seftor EA, et al. Effects of Angiogenesis Inhibitors on Vascular Network Formation by Human Endothelial and Melanoma Cells. J Nat Cancer Inst 2004; 96(19): 1473-1477.
56. Zhang S, Li M, Gu Y, et al. Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. J Exp Clin Cancer Res 2008; 27: 60.